Kluckova Katarina, Bezawork-Geleta Ayanachew, Rohlena Jakub, Dong Lanfeng, Neuzil Jiri
Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech Republic.
Biochim Biophys Acta. 2013 May;1827(5):552-64. doi: 10.1016/j.bbabio.2012.10.015. Epub 2012 Nov 6.
With the arrival of the third millennium, in spite of unprecedented progress in molecular medicine, cancer remains as untamed as ever. The complexity of tumours, dictating the potential response of cancer cells to anti-cancer agents, has been recently highlighted in a landmark paper by Weinberg and Hanahan on hallmarks of cancer [1]. Together with the recently published papers on the complexity of tumours in patients and even within the same tumour (see below), the cure for this pathology seems to be an elusive goal. Indisputably, the strategy ought to be changed, searching for targets that are generally invariant across the landscape of neoplastic diseases. One such target appears to be the mitochondrial complex II (CII) of the electron transfer chain, a recent focus of research. We document and highlight this particularly intriguing target in this review paper and give examples of drugs that use CII as their molecular target. This article is part of a Special Issue entitled: Respiratory complex II: Role in cellular physiology and disease.
随着第三个千年的到来，尽管分子医学取得了前所未有的进展，但癌症依旧如往昔般难以控制。肿瘤的复杂性决定了癌细胞对抗癌药物的潜在反应，这一点最近在温伯格和哈纳汉关于癌症特征的一篇具有里程碑意义的论文中得到了强调[1]。连同最近发表的关于患者肿瘤甚至同一肿瘤内部复杂性的论文（见下文），治愈这种疾病似乎是一个难以实现的目标。无可争议的是，策略应该改变，要寻找在肿瘤性疾病领域普遍不变的靶点。其中一个这样的靶点似乎是电子传递链的线粒体复合物II（CII），它是最近研究的焦点。在这篇综述论文中，我们记录并强调了这个特别引人关注的靶点，并给出了以CII为分子靶点的药物实例。本文是名为《呼吸复合物II：在细胞生理学和疾病中的作用》特刊的一部分。
